RecruitingPhase 1NCT07340138
Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
A Phase 1b Study of Pelabresib (DAK539) add-on to Stable Dose of Ruxolitinib in Japanese Adult Patients With Myelofibrosis
Sponsor
Novartis Pharmaceuticals
Enrollment
6 participants
Start Date
Apr 15, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
This Phase 1b, multicenter, open-label study aims to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of pelabresib as add-on to ruxolitinib in Japanese patients with myelofibrosis (MF).
Eligibility
Min Age: 18 Years
Inclusion Criteria7
- Participants have diagnosis of primary myelofibrosis (PMF), post-polycythemia vera MF (Post-PV MF) or post-essential thrombocythemia MF (Post-ET MF) according to the International Consensus Classification (ICC) for Myeloid Neoplasms and Acute Leukemias 2022.
- DIPSS risk category intermediate-1, intermediate-2 or high-risk at screening.
- Participants currently treated with ruxolitinib monotherapy AND who are likely to benefit from the addition of pelabresib to ruxolitinib in the opinion of the investigator.
- Receiving ruxolitinib at a stable dose (5 to 25 mg BID) for at least 8 weeks prior to the first dose of pelabresib.
- Palpable spleen (spleen length below left costal margin \[LCM\] must be recorded) or documented splenomegaly by MRI or CT (image report must be recorded) at screening.
- Platelet count ≥ 100 × 10\^9/L in the absence of growth factor support (including thrombopoietin mimetics/agonists) or platelet transfusions 4 weeks prior to the first dose of pelabresib.
- Blasts < 5% in peripheral blood. Assessment of blasts in peripheral blood is mandatory at screening.
Exclusion Criteria5
- Prior splenectomy at any time or splenic irradiation in the previous 6 months
- Prior hematopoietic cell transplant or participants anticipated to receive a hematopoietic cell transplant within 24 weeks from the first dose of pelabresib.
- Blasts ≥ 5% in bone marrow if results available at screening or history of accelerated phase or leukemic transformation.
- History of a malignancy (other than MF, PV or ET) except for adequately treated local basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requiring only hormonal therapy and with normal prostate-specific antigen for ≥ 1 year prior to start of pelabresib, adequately treated Stage 1 or 2 cancer currently in complete remission, or any other cancer that has been in complete remission for ≥ 3 years
- Received any approved or investigational agent for the treatment of MF except ruxolitinib within 14 days of first dose of pelabresib or within 5 half-lives of the approved or investigational agent, whichever is longer.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGPelabresib
125 mg orally once daily (QD) on Days 1-14 of each 21-day cycle
DRUGRuxolitinib
5-25 mg twice daily (BID)
Locations(6)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07340138
Related Trials
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT073577275 locations
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
NCT074698911 location
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
NCT073622252 locations
Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis
NCT067708421 location